Mild cognitive disorder
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Analysis implied that APOE ε4 might affect CSF YKL-40 levels in MCI subjects, suggesting a crucial role of APOE ε4 in neuroinflammation in detecting individuals who might convert to AD from MCI and, thus, as an effective predictive factor.
|
31794792 |
2020 |
Mild cognitive disorder
|
0.090 |
Biomarker
|
disease |
BEFREE |
Higher levels of sTNFR2 (0.265, p<0.05), IL-6 (0.129, p<0.05) and MCP-1 (0.779, p<0.05) and lower levels of IL-8 (-1.293, p<0.05) in the periphery, as well as elevated concentrations of YKL-40 (0.373, p<0.05), VILIP-1 (0.534, p<0.005) and sTREM2 (0.695, p<0.05) in CSF, were shown in MCI compared with the control.
|
30630955 |
2019 |
Mild cognitive disorder
|
0.090 |
Biomarker
|
disease |
BEFREE |
We analyzed 5 validated pathophysiological cerebrospinal fluid biomarkers (Aβ<sub>1-42</sub>, t-tau, p-tau<sub>181</sub>, NFL, YKL-40) in 113 participants (healthy controls [N = 20], subjective memory complainers [N = 36], mild cognitive impairment [N = 20], and AD dementia [N = 37], age: 66.7 ± 10.4, 70.4 ± 7.7, 71.7 ± 8.4, 76.2 ± 3.5 years [mean ± SD], respectively) using Density-Based Spatial Clustering of Applications with Noise, which does not require a priori determination of the number of clusters.
|
31585366 |
2019 |
Mild cognitive disorder
|
0.090 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease.
|
30311914 |
2018 |
Mild cognitive disorder
|
0.090 |
Biomarker
|
disease |
BEFREE |
The diagnostic and classificatory performances of all combinations of three core (amyloid β peptide [i.e., Aβ<sub>1-42</sub>], total tau [t-tau], and phosphorylated tau) and three novel (neurofilament light chain protein, neurogranin, and YKL-40) cerebrospinal fluid biomarkers of neurodegeneration were compared among individuals with mild cognitive impairment (n = 41), Alzheimer's disease dementia (ADD; n = 35), frontotemporal dementia (FTD; n = 9), and cognitively healthy controls (HC; n = 21), using 10-fold cross-validation.
|
29328927 |
2018 |
Mild cognitive disorder
|
0.090 |
Biomarker
|
disease |
BEFREE |
YKL-40 was compared among HCs (n = 21), mild cognitive impairment (n = 41), AD (n = 35), and FTD (n = 9) (level I) and among HCs (n = 21), AD pathophysiology (tau and amyloid β) negative (n = 15), tau positive (n = 15), amyloid β positive (n = 13), AD pathophysiology positive (n = 33), and FTD (n = 9) (level II).
|
28263742 |
2017 |
Mild cognitive disorder
|
0.090 |
Biomarker
|
disease |
BEFREE |
CSF YKL-40 concentrations have been shown to predict progression from prodromal mild cognitive impairment to AD dementia.
|
28281838 |
2017 |
Mild cognitive disorder
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
CSF concentrations of YKL-40 were significantly higher in MCI and AD patients, whereas CSF levels of VILIP-1 were statistically higher in the AD group as compared to the subjects without cognitive deficits.
|
28697565 |
2017 |
Mild cognitive disorder
|
0.090 |
Biomarker
|
disease |
BEFREE |
Brain magnetic resonance imaging (MRI) scans were acquired in 110 participants (49 control; 19 preclinical; 27 mild cognitive impairment [MCI] due to AD; 15 mild AD dementia) and CSF concentrations of YKL-40 and sTREM2 were determined.
|
28149943 |
2017 |